Genetic Technological Innovations (GTI) specializes in providing a range of clinical laboratory services, focusing on rapid and accurate diagnostic testing. Their offerings include rapid COVID testing, toxicology, respiratory pathogen panel (RPP) testing, gastrointestinal (GI) testing, and urinary tract infection (UTI) and sexually transmitted infection (STI) testing. GTI emphasizes the importance of quick and efficient diagnostics, aiming to facilitate timely treatment for patients. Their commitment to accuracy and cost-effectiveness is evident in their mission to serve both medical professionals and patients.

Founded in 2013, GTI has established itself as a reputable laboratory by obtaining CLIA and CAP licenses and securing certifications to operate in 49 states, excluding New York. Over the years, the company has developed a comprehensive suite of test panels and menus, particularly in toxicology and molecular testing. Their focus on innovation and quality in laboratory services positions GTI as a valuable resource in the healthcare sector, dedicated to enhancing patient outcomes through advanced diagnostic solutions.

United States

State-of-the-art diagnostic laboratory providing comprehensive pathology, DNA Sequencing, pharmacogenetic and toxicology testing solutions.

Genetic Technological Innovations

Company Details